Story perspectives

Novo Nordisk CEO Pledges Acquisitions After 8% Share Drop

By Drooid · Sep 22, 2026, 2:54 PM UTC · How we work

Summary

Story summary

Novo Nordisk CEO Mike Doustdar announced the company will pursue acquisitions to fill pipeline gaps.
Novo Nordisk shares fell nearly 8% on Monday, its steepest decline since February.
The firm aims to launch five blockbuster drugs by 2030 and target 150 billion crowns in pipeline sales by 2035.
Novo will launch the CagriSema combo early next year and cagrilintide by 2028.

1 of 1

Story summary

Novo Nordisk CEO Mike Doustdar announced the company will pursue acquisitions to fill pipeline gaps.
Novo Nordisk shares fell nearly 8% on Monday, its steepest decline since February.
The firm aims to launch five blockbuster drugs by 2030 and target 150 billion crowns in pipeline sales by 2035.
Novo will launch the CagriSema combo early next year and cagrilintide by 2028.